Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. [electronic resource]
Producer: 20050405Description: 1612-9 p. digitalISSN:- 1098-4275
- Ambulatory Care -- economics
- Antibodies, Monoclonal -- economics
- Antibodies, Monoclonal, Humanized
- Antiviral Agents -- economics
- Bronchiolitis -- economics
- Cohort Studies
- Cost Savings
- Cost-Benefit Analysis
- Direct Service Costs
- Health Care Surveys
- Hospital Mortality
- Hospitalization -- economics
- Humans
- Infant
- Infant, Newborn
- Infant, Premature
- Medicaid -- statistics & numerical data
- Models, Economic
- North Carolina
- Palivizumab
- Regression Analysis
- Respiratory Syncytial Virus Infections -- economics
- Respiratory Syncytial Virus, Human
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.